{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:01:13Z","timestamp":1783980073650,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1 DA01583"],"award-info":[{"award-number":["UG1 DA01583"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s11606-025-10035-5","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:18:58Z","timestamp":1762870738000},"page":"1138-1141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Actions Needed for Pharmacy-Dispensed Methadone for Opioid Use Disorder in the United States"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8116-6023","authenticated-orcid":false,"given":"Zoe M.","family":"Weinstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bratberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Joudrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"10035_CR1","doi-asserted-by":"publisher","unstructured":"Andrews CM, Feltus SR, Horgan CM, Thomas CP, Hodgkin D, Stewart MT. Coverage for Opioid Use Disorder Medications in Medicaid Managed Care. JAMA Health Forum. 2025;6(9):e253239. https:\/\/doi.org\/10.1001\/jamahealthforum.2025.3239","DOI":"10.1001\/jamahealthforum.2025.3239"},{"key":"10035_CR2","doi-asserted-by":"publisher","unstructured":"Baylis JD, Jorgenson TL, Pals HE, et al. Clinical pharmacist practitioners prescribing of buprenorphine for opioid use disorder. Drug Alcohol Depend. 2025;271:112663. https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.112663","DOI":"10.1016\/j.drugalcdep.2025.112663"},{"key":"10035_CR3","doi-asserted-by":"publisher","unstructured":"Brooner RK, Stoller KB, Patel P, Wu LT, Yan H, Kidorf M. Opioid treatment program prescribing of methadone with community pharmacy dispensing: Pilot study of feasibility and acceptability. Drug Alcohol Depend Rep. 2022;3:100067. https:\/\/doi.org\/10.1016\/j.dadr.2022.100067","DOI":"10.1016\/j.dadr.2022.100067"},{"key":"10035_CR4","doi-asserted-by":"publisher","unstructured":"Das S, Muhetaer K, Gandotra N, Tomoyasu N. Filling the Treatment Gap: Geographic Expansion of Buprenorphine Providers Across the U.S. AJPM Focus. 2025;4(1):100284. https:\/\/doi.org\/10.1016\/j.focus.2024.100284","DOI":"10.1016\/j.focus.2024.100284"},{"key":"10035_CR5","doi-asserted-by":"publisher","unstructured":"Incze MA, Simon C, Suen LW. Methadone\u2019s Moment. JAMA. Published online October 17, 2024. https:\/\/doi.org\/10.1001\/jama.2024.19914","DOI":"10.1001\/jama.2024.19914"},{"key":"10035_CR6","unstructured":"Institute of Medicine (US) Committee on Federal Regulation of Methadone Treatment. Introduction. In: Rettig RA, Yarmolinsky A, eds. Federal Regulation of Methadone Treatment. National Academies Press (US); 1995. Accessed September 19, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK232114\/"},{"key":"10035_CR7","doi-asserted-by":"publisher","unstructured":"Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment. Am J Public Health. 2015;105(8):e55-e63. https:\/\/doi.org\/10.2105\/AJPH.2015.302664","DOI":"10.2105\/AJPH.2015.302664"},{"key":"10035_CR8","doi-asserted-by":"publisher","unstructured":"Krawczyk N, Joudrey PJ, Simon R, Russel DM, Frank D. Recent modifications to the US methadone treatment system are a Band-Aid\u2014not a solution\u2014to the nation\u2019s broken opioid use disorder treatment system. Health Aff Sch. 2023;1(1):qxad018. https:\/\/doi.org\/10.1093\/haschl\/qxad018","DOI":"10.1093\/haschl\/qxad018"},{"key":"10035_CR9","doi-asserted-by":"publisher","unstructured":"Liu R, Beetham T, Newton H, Busch SH. Access to treatment before and after Medicare coverage of opioid treatment programs. Health Aff Sch. 2024;2(6):qxae076. https:\/\/doi.org\/10.1093\/haschl\/qxae076","DOI":"10.1093\/haschl\/qxae076"},{"key":"10035_CR10","doi-asserted-by":"publisher","unstructured":"McCarty D, Bougatsos C, Chan B, et al. Office-Based Methadone Treatment for Opioid Use Disorder and Pharmacy Dispensing: A Scoping Review. Am J Psychiatry. 2021;178(9):804-817. https:\/\/doi.org\/10.1176\/appi.ajp.2021.20101548","DOI":"10.1176\/appi.ajp.2021.20101548"},{"key":"10035_CR11","doi-asserted-by":"publisher","unstructured":"McGinty EE, White SA, Eisenberg MD, Palmer NR, Brown CH, Saloner BK. US payment policy for medications to treat opioid use disorder: landscape and opportunities. Health Aff Sch. 2024;2(3):qxae024. https:\/\/doi.org\/10.1093\/haschl\/qxae024","DOI":"10.1093\/haschl\/qxae024"},{"key":"10035_CR12","doi-asserted-by":"publisher","unstructured":"Moon KJ, Linton SL, Kazerouni NJ, Levander XA, Irwin AN, Hartung DM. Association of economic and racial segregation with restricted buprenorphine dispensing in U.S. community pharmacies. Drug Alcohol Depend Rep. 2024;12:100255. https:\/\/doi.org\/10.1016\/j.dadr.2024.100255","DOI":"10.1016\/j.dadr.2024.100255"},{"key":"10035_CR13","doi-asserted-by":"publisher","unstructured":"Nosyk B, Min JE, Homayra F, et al. Buprenorphine\/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. JAMA. 2024;332(21):1822-1831. https:\/\/doi.org\/10.1001\/jama.2024.16954","DOI":"10.1001\/jama.2024.16954"},{"key":"10035_CR14","doi-asserted-by":"publisher","unstructured":"Onuoha EN, Leff JA, Schackman BR, McCollister KE, Polsky D, Murphy SM. Economic Evaluations of Pharmacological Treatment for Opioid Use Disorder: a Systematic Literature Review. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2021;24(7):1068-1083. https:\/\/doi.org\/10.1016\/j.jval.2020.12.023","DOI":"10.1016\/j.jval.2020.12.023"},{"key":"10035_CR15","doi-asserted-by":"publisher","unstructured":"Ostrach B, Carpenter D, Cote LP. DEA Disconnect Leads to Buprenorphine Bottlenecks. J Addict Med. 2021;15(4):272. https:\/\/doi.org\/10.1097\/ADM.0000000000000762","DOI":"10.1097\/ADM.0000000000000762"},{"key":"10035_CR16","unstructured":"Rep. Tonko P [D N 20. Text - H.R.9886 - 118th Congress (2023\u20132024): BUPE for Recovery Act. September 27, 2024. Accessed September 29, 2025. https:\/\/www.congress.gov\/bill\/118th-congress\/house-bill\/9886\/text"},{"key":"10035_CR17","doi-asserted-by":"publisher","unstructured":"Rodriguez MI, Hersh A, Anderson LB, Hartung DM, Edelman AB. Association of Pharmacist Prescription of Hormonal Contraception With Unintended Pregnancies and Medicaid Costs. Obstet Gynecol. 2019;133(6):1238-1246. https:\/\/doi.org\/10.1097\/AOG.0000000000003265","DOI":"10.1097\/AOG.0000000000003265"},{"key":"10035_CR18","unstructured":"The Mental Health Parity and Addiction Equity Act 10th Anniversary. ParityTrack. Accessed September 29, 2025. https:\/\/www.paritytrack.org\/mhpaea-10th-anniversary\/"},{"key":"10035_CR19","doi-asserted-by":"publisher","unstructured":"Varisco TJ, Thornton D, Hussain T, et al. Addressing wholesale distributor barriers to buprenorphine access: Consensus recommendations from the PhARM-OUD expert panel. Drug Alcohol Depend Rep. 2025;16:100360. https:\/\/doi.org\/10.1016\/j.dadr.2025.100360","DOI":"10.1016\/j.dadr.2025.100360"},{"key":"10035_CR20","doi-asserted-by":"publisher","unstructured":"Volkow ND. The epidemic of fentanyl misuse and overdoses: challenges and strategies. World Psychiatry. 2021;20(2):195-196. https:\/\/doi.org\/10.1002\/wps.20846","DOI":"10.1002\/wps.20846"},{"key":"10035_CR21","doi-asserted-by":"publisher","unstructured":"Winstanley EL, Gray A, Thornton D. Addressing the Escalating Problems That Patients Encounter When Filling Buprenorphine Prescriptions. JAMA Psychiatry. Published online October 16, 2024. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.3076","DOI":"10.1001\/jamapsychiatry.2024.3076"},{"key":"10035_CR22","doi-asserted-by":"publisher","unstructured":"Wu LT, John WS, Morse ED, et al. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial. Addiction. 2022;117(2):444-456. https:\/\/doi.org\/10.1111\/add.15641","DOI":"10.1111\/add.15641"},{"key":"10035_CR23","doi-asserted-by":"publisher","unstructured":"Wu LT, Mannelli P, John WS, Anderson A, Schwartz RP. Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff. Subst Abuse Treat Prev Policy. 2023;18(1):55. https:\/\/doi.org\/10.1186\/s13011-023-00563-w","DOI":"10.1186\/s13011-023-00563-w"},{"key":"10035_CR24","unstructured":"Yale University. Office-Based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment - A Pragmatic Hybrid Effectiveness/Implementation Trial. clinicaltrials.gov; 2025. Accessed September 29, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06323824"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10035-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-10035-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-10035-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:25:26Z","timestamp":1774283126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-10035-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10035"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-10035-5","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}},{"value":"Dr. Weinstein serves as the site medical director for a BayMark methadone clinic, with her employer, Boston University, paid a per diem rate for her time. Dr. Weinstein reported honorarium payment for serving as a member of the three advisory committees outside of the submitted work: the Producing Outcome Measures for OTP Quality Improvement (PROMOTe-QI) Health Professional Advisory Committee (from RTI International and the UCLA, funding from the National Institute on Drug Abuse), the National Coalition to Liberate Methadone, Post Conference Working Group (funded by the PEW Foundation), and the Pharmacy-Centered Methadone Access in North Carolina Clinical Advisory Board (funded through the NC Collaboratory). No other disclosures were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}